Clinical Trials Logo

Carcinoid Tumors clinical trials

View clinical trials related to Carcinoid Tumors.

Filter by:

NCT ID: NCT02859064 Terminated - Clinical trials for Neuroendocrine Tumors

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Start date: July 28, 2017
Phase: Phase 2
Study type: Interventional

Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver. Lanreotide (Somatuline® Depot) Injection and Yttrium-90 microspheres (SIR-Spheres®) each have FDA approval to treat patients with metastatic NETs. The purpose of this study is to determine if treatment for patients with NETs can be optimized by combining these therapies.

NCT ID: NCT02795858 Active, not recruiting - Carcinoid Tumors Clinical Trials

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Start date: June 14, 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

NCT ID: NCT02575300 Completed - Carcinoid Tumors Clinical Trials

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Start date: October 9, 2015
Phase: Phase 2
Study type: Interventional

This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs). The purpose of this study is to test any good and bad effects of the study drug called Ibrutinib. The study population will consist of adult patients with histologically confirmed low to intermediate grade NETs of the GI tract, lungs and unknown primary (carcinoid tumors) or pNETs. All patients must be confirmed to have advanced disease. The study will enroll up to 51 patients in two cohorts (30 carcinoid and 21 pNET patients).

NCT ID: NCT02441088 Active, not recruiting - Neuroblastoma Clinical Trials

Theranostics: 68GaDOTATOC and 90YDOTATOC

PRRT
Start date: May 2015
Phase: Phase 2
Study type: Interventional

Participants in this research study have tumors that express somatostatin receptors such as neuroendocrine tumors, medulloblastoma, meningioma, and neuroblastoma. Approximately 64 people will participate in this study conducted at the University of Iowa.

NCT ID: NCT02441062 Completed - Neuroblastoma Clinical Trials

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.

NCT ID: NCT02359500 Terminated - Clinical trials for Neuroendocrine Tumors

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with Somatostatin receptor expressing tumors who undergo imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors. 68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either at staging or during follow up.

NCT ID: NCT02177773 Terminated - Neuroblastoma Clinical Trials

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

DOTA-TOC
Start date: June 23, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.

NCT ID: NCT01980732 No longer available - Carcinoid Tumors Clinical Trials

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

NCT ID: NCT01731925 Active, not recruiting - Carcinoid Tumors Clinical Trials

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

SUNLAND
Start date: January 7, 2013
Phase: Phase 2
Study type: Interventional

Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.

NCT ID: NCT01619865 Completed - Neuroblastoma Clinical Trials

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

GA-68
Start date: February 21, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.